More than $582 Billion in New U.S. Investment Since 2025
America leads the world in healthcare innovation and access, and a strong medical infrastructure is essential to maintain this standing for our national security.
The world’s pharmaceutical companies are stepping up their investments in America.
We Work For Health’s tracking tool, the U.S. Biopharma Investment Watch, is documenting these developments and providing visibility into the sector's robust expansion and critical role in securing America's position as the global leader in health care innovation. Since January 2025, companies have committed to investing more than $582 billion to bolster U.S. research and development, expand manufacturing, and create jobs across the country.
Investment in America
These investments bring cutting edge treatments closer to the patients who need them while bolstering America’s position as a world leader in healthcare access and innovation. The positive impact of these investments reaches deep into U.S. communities, powering high-skill positions for scientists and engineers, construction and production support roles, and millions of jobs for the communities surrounding the facilities. This builds upon more than 4.9 million total U.S. jobs and $71.6 billion in vendor spending in states along with $2.6B in wages paid to the American construction workforce.
The tracker reflects the sector’s commitment to preserving American leadership in the life sciences, as China continues a coordinated campaign to overtake it.
1,488%
increase in announced U.S. facility investments in 2025 vs 2024
Tens of Thousands
of new construction jobs across America
Faster delivery
of breakthrough medicines to U.S. patients
It’s essential to have the right policies in place that encourage continued investment to secure America’s future as the global leader in life sciences.
U.S. Biopharma Investment Watch
Legend:
Announcement date
Company
Investment amount
Investment location(s)
Jan 20, 2026
Roche
$1.3 billion
Holly Springs-NC
An expansion of Genentech’s (Roche’s U.S. subsidiary) initial $700 million investment in a new fill-finish biologics plant, bringing the total investment in this facility to $2 billion.
The expanded investment will include additional production capacity and support an additional 100 new jobs once completed.
Part of a larger, previously announced $50 billion company investment.
Jan 12, 2026
AbbVie
$90 billion
Unspecified location
Pledging an additional $90 billion toward U.S.-based research and development and capital investments, including manufacturing, over the next decade to bring the company’s total commitment to $100 billion.
AbbVie previously committed to a $10 billion U.S. expansion in April 2025.
Jan 9, 2026
Novartis
Unspecified
Winter Park-FL
A new radioligand therapy (RLT) manufacturing site is expected to come online by 2029 and strengthen the company’s specialized supply chain and manufacturing capabilities across its network of RLT production facilities.
Part of a larger, previously announced $23 billion company investment.
Dec 9, 2025
Eli Lilly
$6 billion
Huntsville-AL
A new, next-generation active pharmaceutical ingredient (API) facility that will support the production of small molecule synthetic and peptide medicines, including an oral GLP-1. The project will bring “450 high-value jobs” to the area, including engineers, scientists, operations personnel and lab technicians, and 3,000 construction jobs.
Part of a larger, previously announced $27 billion company investment.
Nov 21, 2025
AstraZeneca
$2 billion
Frederick-MD, Gaithersburg-MD
Expansion of the company’s flagship biologics manufacturing facility in Frederick and the construction of a new state-of-the-art facility in Gaithersburg for the development of innovative molecules to be used in clinical trials.
The investment will support 2,600 jobs across the two sites, including the retention of local jobs, construction activity, and the creation of 300 highly skilled jobs.
Part of a larger, previously announced $50 billion company investment.
Nov 19, 2025
Novartis
Unspecified
Durham-NC, Morrisville-NC
A new site in Durham featuring two facilities dedicated to manufacturing biologics and sterile packaging. Also an expansion of an existing Durham facility with the added capability to support sterile filling of biologics into syringes and vials.
A new site in Morrisville with one facility for the production of solid dosage tablets and capsules, including packaging.
These investments are expected to create 700 new jobs in North Carolina by 2030 and support more than 3,000 indirect jobs across the Novartis U.S. supply chain.
Part of a larger, previously announced $23 billion company investment.
Oct 29, 2025
Eli Lilly
$1.2 billion
Carolina-PR
Expansion and modernization of the Lilly del Caribe manufacturing site to support the company's growing portfolio of oral solid medicines in cardiometabolic health, neuroscience, oncology and immunology. The project will generate an estimated 1,000 construction jobs and 100 additional high-tech manufacturing positions.
Part of a larger, previously announced $27 billion company investment.
No entries found matching your criteria. Please modify your filters.
Methodology
All investments data comes from publicly available resources. Investments may span across multiple states and, therefore, are reflected on each state page. Investment locations will be updated once specified.
-
Jobs data source: WWFH “in the states” page
-
Labor hours data source: PILMA jobs report page